Bausch + Lomb Corp.’s stock soared 10% early Wednesday, after the vision-care company’s adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024. The Vaughan, Ontario-based company BLCO, +1.96% had a net loss of $54 million, or 15 cents a share, for the quarter, after a loss of $1 million in the year-earlier period. Adjusted per-share earnings came to 24 cents, ahead of the 17-cent FactSet consensus.Revenue rose to $1.173 billion from $996 million a year ago, also ahe ...

9 1. Products with sales outside the United States impacted by F/X changes. 2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios. 3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the repo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) ...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance VAUGHAN, Ontario, Feb. 21, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full year 2023 financial results. Select Fourth-Quarter Company Highlights ___________________________________ 1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and n ...

Analysts on Wall Street project that Bausch + Lomb (BLCO) will announce quarterly earnings of $0.17 per share in its forthcoming report, representing a decline of 26.1% year over year. Revenues are projected to reach $1.09 billion, increasing 9.6% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 18.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Bausch + Lomb (BLCO) . This company, which is in the Zacks Medical Services industry, shows potential for another earnings beat.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 17.36%, on average, in the last two quarters.For t ...

The market expects Bausch + Lomb (BLCO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 21, 2024, might help the stock move higher if these key number ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start ...

Financial Data and Key Metrics Changes - Total company revenue for Q3 2023 was $1.007 billion, reflecting an 8% increase on a constant currency basis and a 7% increase on a reported basis compared to the prior year [12][11][27] - Adjusted gross margin for the quarter was 61.3%, up 80 basis points compared to Q3 2022 [24] - Adjusted EBITDA for Q3 was $187 million, negatively impacted by currency headwinds of approximately $14 million and Lynchburg-related disruptions of $7 million [54][26] Business Line Data and Key Metrics Changes - Vision Care revenue was $648 million, increasing by 11% on a constant currency basis, driven by growth in both consumer and contact lens portfolios [15] - Revenue from the Pharma segment was $174 million, representing constant currency growth of 1%, with VYZULTA growing by 54% [22][40] - The lens care portfolio grew by 8% on a constant currency basis, while the implantables segment declined by 2% [17][19] Market Data and Key Metrics Changes - The consumer business grew by 14% on a constant currency basis, led by LUMIFY, Eye Vitamins, and Artelac franchises [45] - The China business was down 1% on a constant currency basis, but year-to-date constant currency growth in China has been 6% [44] - Daily SiHy lenses reported a 79% revenue growth in the quarter [47] Company Strategy and Development Direction - The company is focused on addressing supply chain challenges and has made significant investments in improving its distribution facilities [10][62] - The launch of MIEBO and the acquisition of XIIDRA are seen as transformative for the Pharma business, with a strong emphasis on the Dry Eye Disease market [23][66] - The company expects 2024 to be one of the most active launch years in its history, with plans to strengthen its leadership in Dry Eye Disease [87][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fundamentals of the eye care market remaining strong, with overall market growth expected to be mid-single digits [29] - The company anticipates currency headwinds to revenue of approximately $100 million in 2024, which will be monitored closely [31] - Management acknowledged the need for continued investment in product launches and the importance of maintaining high-quality supply [116][88] Other Important Information - The company raised its revenue guidance for 2023 to a range of $4.035 billion to $4.085 billion, reflecting a constant currency growth rate of approximately 9.5% to 10.5% [27] - The adjusted tax rate for the third quarter was 6%, in line with expectations for the full year [26] - The company is committed to investing in R&D, with approximately 8% of revenue allocated to this area [25] Q&A Session Summary Question: What is the outlook for XIIDRA and MIEBO sales next year? - Management indicated that XIIDRA is expected to stabilize and potentially achieve mid-single-digit growth, while MIEBO is showing promising early trends [78][76] Question: How is the company addressing supply chain issues? - Management emphasized a practical approach to supply chain improvements, with ongoing investments and strategic sourcing to enhance product availability [62][90] Question: What is the impact of the FDA warning on eye drops? - While the company was not directly affected, management noted that it underscores the importance of quality control and may create some market opportunities [116]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other ...